Xentria Advances Pulmonary Sarcoidosis Drug Candidate Following FDA Consultation

Clinical-stage biotech Xentria has received positive FDA feedback regarding its XTMAB-16 program for pulmonary sarcoidosis, clearing regulatory pathways for continued clinical development and potential next-phase trials.

1 Sept, 11:00 — 1 Sept, 11:00

Post Share

Sources

Showing 1 of 1 sources

morningstar11h ago

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback - Morningstar

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback Morningstar

Read full article →

Xentria Advances Pulmonary Sarcoidosis Drug Candidate Following FDA Consultation

Sources

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback - Morningstar

Related Stories

N1 and CNN Confirm Expiration of Broadcasting Partnership Agreement

U.S. Equity Markets See Midday Swings Led by Palo Alto Networks Activity

SB Energy Files for IPO Revealing Major Investments from Nvidia and OpenAI

Enovis Announces Binding Offer to Acquire Surgical Robotics Firm eCential